-

Nexus Pharmaceuticals Stands Ready to Support Efforts to Increase Vaccine Manufacturing

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Nexus Pharmaceuticals supports the Biden-Harris administration’s decision to invoke the Defense Production Act (DPA) in order to boost supplies needed for COVID-19 vaccine production and for at-home virus test kits. This decision, announced by the White House COVID-19 Task Force last week, is a first step towards implementing important measures to ensure the safety of the American people by increasing the availability of vaccines, tests, and supplies.

As one of the nation’s leading specialty drug developers, Nexus stands ready to serve and support any efforts to increase vaccine manufacturing. Expediting the production of vaccines will ultimately increase domestic supply, provide greater opportunity for vaccination and coverage, and will lessen the potential impact of new variants of the virus.

Due to the brand-new manufacturing capacity of our state-of-the-art facility in Wisconsin, Nexus will be able to maintain the production of existing products and simultaneously begin manufacturing vaccines. Unlike many veteran drug manufacturers, Nexus’ unique position ensures that it will not sacrifice the production of one critical-need drug for another. This position makes Nexus an ideal candidate to manufacture 10-20 million doses of life-saving COVID-19 vaccines monthly, ensuring that patients are able to receive life-saving medications when they need it most. Given our unique ability to increase vaccine manufacturing for any of the five vaccine developers, we stand ready to assist any of the vaccine developers and the United States government in their quest to ramp up vaccine manufacturing.

For more information about our state-of-the-art manufacturing facility, including more facts and Live Cam, please visit https://www.nexuspharma.net/project-tomorrow/.

About Nexus Pharmaceuticals Inc.

Nexus Pharmaceuticals Inc., a US-based privately held, women & minority owned healthcare company, specializing in innovative processes to make difficult-to-manufacture specialty and generic drugs that are easier to use, less labor intensive, and more streamlined in practice. Nexus ensures that its high-quality FDA-approved drugs fulfill a critical unmet medical need and delivers dependable life-saving treatment options when and where they’re needed most.

Contacts

Deana Mndrucic
dmndrucic@nexuspharma.net
847-996-3790

Nexus Pharmaceuticals Inc.


Release Summary
As one of the nation’s leading specialty drug developers, Nexus Pharmaceuticals stands ready to support efforts to increase vaccine manufacturing.
Release Versions

Contacts

Deana Mndrucic
dmndrucic@nexuspharma.net
847-996-3790

Social Media Profiles
More News From Nexus Pharmaceuticals Inc.

Nexus Pharmaceuticals Launches Baclofen Injection Refill Kit

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Nexus Pharmaceuticals, LLC announces the launch of their Baclofen Injection Refill Kit. Nexus’ kit will be the only one on the market that offers a vial presentation. “We are proud to be supplying healthcare systems with not only a life-changing drug, such as Baclofen, but also with a convenience kit to deliver the medication in a safe, accommodating, and timely fashion,” says Omair Ahmed, Chief Operating Officer at Nexus. “This kit will ease the lives of th...

Nexus Pharmaceuticals Launches Fluorescein 2 mL

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Nexus Pharmaceuticals, LLC is expanding their Fluorescein dosage options to include Fluorescein Injection, USP 25% in a 2 mL vial alongside Fluorescein Injection, USP 10% in a 5 mL vial. Nexus is committed to enhancing the availability of Fluorescein across the optometry market. Fluorescein 2 mL and 5 mL are available in cartons of ten. Order your supply of 2 mL Fluorescein Injection, USP 25% directly through your Wholesalers or from Customer Service at (888...

Nexus Pharmaceuticals Launches Tranexamic Acid

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Nexus Pharmaceuticals, LLC announced the launch of Tranexamic Acid. This milestone is another step for Nexus in its mission to provide life-saving medication to those who need it most. “We are very excited to be adding Tranexamic Acid to our product portfolio,” says Vince LoPiccolo, Vice President of Sales at Nexus. “Antifibrinolytic Agents, such as Tranexamic Acid, are crucial to have available in operating rooms and we are proud to contribute to the supply...
Back to Newsroom